Table 1.
Cohort Characteristics by Statin Use
| Overall (N = 601,934 [100%]) | High-Intensity Statin (n = 135,569 [22.5%]) | Other Statin (n = 166,231 [27.6%]) | No Statin (n = 300,134 [49.9%]) | P Value | |
|---|---|---|---|---|---|
|
| |||||
| Age, y | 67.5 ± 13.3 | 65.9 ± 11.1 | 70.0 ± 11.9 | 66.9 ± 14.7 | <0.0001 |
| <45 (younger) | 23,801 (4.0) | 3,017 (2.2) | 2,313 (1.4) | 18,471 (6.1) | <0.0001 |
| 45–74 (middle) | 383,630 (63.7) | 100,247 (73.9) | 100,365 (60.4) | 183,018 (61.0) | <0.0001 |
| ≥75 (older) | 194,503 (32.3) | 32,305 (23.8) | 63,553 (38.2) | 98,645 (32.9) | <0.0001 |
| Sex | <0.0001 | ||||
| Female | 250,875 (41.7) | 39,576 (29.2) | 68,778 (41.4) | 142,521 (47.5) | |
| Male | 351,059 (58.3) | 95,993 (70.8) | 97,453 (58.6) | 157,613 (52.5) | |
| Cardiovascular history | |||||
| CAD | 416,349 (69.2) | 114,115 (84.2) | 115,218 (69.3) | 187,016 (62.3) | <0.0001 |
| CeVD | 117,202 (19.5) | 25,843 (19.1) | 34,046 (20.5) | 57,313 (19.1) | <0.0001 |
| PAD | 211,616 (35.2) | 35,269 (26.0) | 58,811 (35.4) | 117,536 (39.2) | <0.0001 |
| ASCVD risk factors | |||||
| Dyslipidemia | 474,823 (78.9) | 123,762 (91.3) | 150,393 (90.5) | 200,668 (66.9) | <0.0001 |
| T2DM | 219,188 (36.4) | 55,717 (41.1) | 68,047 (40.9) | 95,424 (31.8) | <0.0001 |
| Hypertension | 493,050 (81.9) | 118,245 (87.2) | 144,239 (86.8) | 230,566 (76.8) | <0.0001 |
| Obesity | 109,334 (18.2) | 27,009 (19.9) | 29,782 (17.9) | 52,543 (17.5) | <0.0001 |
| Medical comorbidities | |||||
| Charlson comorbidity score ≥3 | 157,451 (26.2) | 32,879 (24.3) | 44,205 (26.6) | 80,367 (26.8) | <0.0001 |
| CKD ≥stage 4 | 16,392 (2.7) | 3,545 (2.6) | 4,663 (2.8) | 8,184 (2.7) | 0.006 |
| Depression | 101,990 (16.9) | 21,218 (15.6) | 26,223 (15.8) | 54,549 (18.2) | <0.0001 |
| Care patterns | |||||
| LDL-C checked last 12 months | 153,305 (25.5) | 38,395 (28.3) | 44,262 (26.6) | 70,648 (23.5) | <0.0001 |
| Ezetimibe/PCSK-9 inhibitor | 27,855 (4.6) | 9,408 (6.9) | 6,597 (4.0) | 11,850 (4.0) | <0.0001 |
| Outpatient visits | 25 (13–44) | 23 (12–42) | 26 (14–45) | 25 (13–45) | <0.0001 |
| Cardiology visit | 426,788 (70.9) | 107,360 (79.2) | 118,717 (71.4) | 200,711 (66.8) | <0.0001 |
| PCP visit | 489,589 (81.3) | 109,261 (80.6) | 136,477 (82.1) | 243,851 (81.3) | <0.0001 |
Values are mean ± SD, n (%), or median IQR.
ASCVD = atherosclerotic cardiovascular disease; CAD = coronary arterydisease; CKD = chronic kidneydisease; LDL-C = low-density lipoprotein cholesterol; PAD = peripheral artery disease; PCP = primary care physician; PCSK-9 = proprotein convertase subtilisin/kexin type 9; PDC = proportion of days covered; T2DM = type 2 diabetes mellitus.